

1 **CANCEROUS DISEASE MODIFYING ANTIBODIES**

2 **Reference to Related Applications:**

3 This application is a continuation-in-part of application S.N. 10/713,642, filed
4 November 13, 2003, which is a continuation of application S.N. 09/727,361, filed November
5 29, 2000, now U.S. Patent 6,657,048, which is a continuation-in-part of application S.N.
6 09/415,278, filed October 8, 1999, now U.S. Patent 6,180,357 B1, the contents of each of
7 which are herein incorporated by reference.

8 **Field of the Invention:**

9 This invention relates to the isolation and production of cancerous disease modifying
10 antibodies (CDMAB) and to the use of these CDMAB in therapeutic and diagnostic processes,
11 optionally in combination with one or more chemotherapeutic agents. The invention further
12 relates to binding assays which utilize the CDMAB of the instant invention.

13 **Background of the Invention:**

14 Each individual who presents with cancer is unique and has a cancer that is as different
15 from other cancers as that person's identity. Despite this, current therapy treats all patients
16 with the same type of cancer, at the same stage, in the same way. At least 30 percent of these
17 patients will fail the first line therapy, thus leading to further rounds of treatment and the
18 increased probability of treatment failure, metastases, and ultimately, death. A superior
19 approach to treatment would be the customization of therapy for the particular individual. The
20 only current therapy that lends itself to customization is surgery. Chemotherapy and radiation

1 treatment cannot be tailored to the patient, and in most cases, surgery by itself is inadequate for
2 producing cures.

3 With the advent of monoclonal antibodies, the possibility of developing methods for
4 customized therapy became more realistic since each antibody can be directed to a single
5 epitope. Furthermore, it is possible to produce a combination of antibodies that are directed to
6 the constellation of epitopes that uniquely define a particular individual's tumor.

7 Having recognized that a significant difference between cancerous and normal cells is
8 that cancerous cells contain antigens that are specific to transformed cells, the scientific
9 community has long held that monoclonal antibodies can be designed to specifically target
10 transformed cells by binding specifically to these cancer antigens. This has given rise to the
11 belief that monoclonal antibodies can serve as "Magic Bullets" to eliminate cancer cells.

12 Monoclonal antibodies isolated in accordance with the teachings of the instantly
13 disclosed invention have been shown to modify the cancerous disease process in a manner
14 which is beneficial to the patient, for example by reducing the tumor burden, and will
15 variously be referred to herein as cancerous disease modifying antibodies (CDMAB) or "anti-
16 cancer" antibodies.

17 At the present time, the cancer patient usually has few options of treatment. The
18 regimented approach to cancer therapy has produced improvements in global survival and
19 morbidity rates. However, to the particular individual, these improved statistics do not
20 necessarily correlate with an improvement in their personal situation.

21 Thus, if a methodology was put forth which enabled the practitioner to treat each tumor
22 independently of other patients in the same cohort, this would permit the unique approach of

1 tailoring therapy to just that one person. Such a course of therapy would, ideally, increase the
2 rate of cures, and produce better outcomes, thereby satisfying a long-felt need.

3 Historically, the use of polyclonal antibodies has been used with limited success in the
4 treatment of human cancers. Lymphomas and leukemias have been treated with human
5 plasma, but there were few prolonged remission or responses. Furthermore, there was a lack
6 of reproducibility and no additional benefit compared to chemotherapy. Solid tumors such as
7 breast cancers, melanomas and renal cell carcinomas have also been treated with human blood,
8 chimpanzee serum, human plasma and horse serum with correspondingly unpredictable and
9 ineffective results.

10 There have been many clinical trials of monoclonal antibodies for solid tumors. In the
11 1980s there were at least 4 clinical trials for human breast cancer which produced only 1
12 responder from at least 47 patients using antibodies against specific antigens or based on tissue
13 selectivity. It was not until 1998 that there was a successful clinical trial using a humanized
14 anti-her 2 antibody in combination with cisplatin. In this trial 37 patients were accessed for
15 responses of which about a quarter had a partial response rate and another half had minor or
16 stable disease progression.

17 The clinical trials investigating colorectal cancer involve antibodies against both
18 glycoprotein and glycolipid targets. Antibodies such as 17-1A, which has some specificity for
19 adenocarcinomas, has undergone Phase 2 clinical trials in over 60 patients with only 1 patient
20 having a partial response. In other trials, use of 17-1A produced only 1 complete response and
21 2 minor responses among 52 patients in protocols using additional cyclophosphamide. Other
22 trials involving 17-1A yielded results that were similar. The use of a humanized murine

1 monoclonal antibody initially approved for imaging also did not produce tumor regression. To
2 date there has not been an antibody that has been effective for colorectal cancer. Likewise
3 there have been equally poor results for lung, brain, ovarian, pancreatic, prostate, and stomach
4 cancers. There has been some limited success in the use of anti-GD3 monoclonal antibodies
5 for melanoma. Thus, it can be seen that despite successful small animal studies that are a
6 prerequisite for human clinical trials, the antibodies that have been tested thus far, have been
7 for the most part, ineffective.

8 Prior Patents:

9 U.S. Patent No. 5,750,102 discloses a process wherein cells from a patient's tumor are
10 transfected with MHC genes which may be cloned from cells or tissue from the patient. These
11 transfected cells are then used to vaccinate the patient.

12 U.S. Patent No. 4,861,581 discloses a process comprising the steps of obtaining
13 monoclonal antibodies that are specific to an internal cellular component of neoplastic and
14 normal cells of the mammal but not to external components, labeling the monoclonal antibody,
15 contacting the labeled antibody with tissue of a mammal that has received therapy to kill
16 neoplastic cells, and determining the effectiveness of therapy by measuring the binding of the
17 labeled antibody to the internal cellular component of the degenerating neoplastic cells. In
18 preparing antibodies directed to human intracellular antigens, the patentee recognizes that
19 malignant cells represent a convenient source of such antigens.

20 U.S. Patent No. 5,171,665 provides a novel antibody and method for its production.
21 Specifically, the patent teaches formation of a monoclonal antibody which has the property of
22 binding strongly to a protein antigen associated with human tumors, e.g. those of the colon and

1 lung, while binding to normal cells to a much lesser degree.

2 U.S. Patent No. 5,484,596 provides a method of cancer therapy comprising surgically
3 removing tumor tissue from a human cancer patient, treating the tumor tissue to obtain tumor
4 cells, irradiating the tumor cells to be viable but non-tumorigenic, and using these cells to
5 prepare a vaccine for the patient capable of inhibiting recurrence of the primary tumor while
6 simultaneously inhibiting metastases. The patent teaches the development of monoclonal
7 antibodies which are reactive with surface antigens of tumor cells. As set forth at col. 4, lines
8 45 et seq., the patentees utilize autochthonous tumor cells in the development of monoclonal
9 antibodies expressing active specific immunotherapy in human neoplasia.

10 U.S. Patent No. 5,693,763 teaches a glycoprotein antigen characteristic of human
11 carcinomas is not dependent upon the epithelial tissue of origin.

12 U.S. Patent No. 5,783,186 is drawn to anti-Her2 antibodies which induce apoptosis in
13 Her2 expressing cells, hybridoma cell lines producing the antibodies, methods of treating
14 cancer using the antibodies and pharmaceutical compositions including said antibodies.

15 U.S. Patent No. 5,849,876 describes new hybridoma cell lines for the production of
16 monoclonal antibodies to mucin antigens purified from tumor and non-tumor tissue sources.

17 U.S. Patent No. 5,869,268 is drawn to a method for generating a human lymphocyte
18 producing an antibody specific to a desired antigen, a method for producing a monoclonal
19 antibody, as well as monoclonal antibodies produced by the method. The patent is particularly
20 drawn to the production of an anti-HD human monoclonal antibody useful for the diagnosis
21 and treatment of cancers.

22 U.S. Patent No. 5,869,045 relates to antibodies, antibody fragments, antibody
McHale & Slavin, P.A. 2056.00029 5

1 conjugates and single chain immunotoxins reactive with human carcinoma cells. The
2 mechanism by which these antibodies function is two-fold, in that the molecules are reactive
3 with cell membrane antigens present on the surface of human carcinomas, and further in that
4 the antibodies have the ability to internalize within the carcinoma cells, subsequent to binding,
5 making them especially useful for forming antibody-drug and antibody-toxin conjugates. In
6 their unmodified form the antibodies also manifest cytotoxic properties at specific
7 concentrations.

8 U.S. Patent No. 5,780,033 discloses the use of autoantibodies for tumor therapy and
9 prophylaxis. However, this antibody is an anti-nuclear autoantibody from an aged mammal. In
10 this case, the autoantibody is said to be one type of natural antibody found in the immune
11 system. Because the autoantibody comes from "an aged mammal", there is no requirement that
12 the autoantibody actually comes from the patient being treated. In addition the patent discloses
13 natural and monoclonal anti-nuclear autoantibody from an aged mammal, and a hybridoma cell
14 line producing a monoclonal anti-nuclear autoantibody.

15 Summary of the Invention:

16 The instant inventors have previously been awarded U.S. Patent 6,180,357, entitled
17 "Individualized Patient Specific Anti-Cancer Antibodies" directed to a process for selecting
18 individually customized anti-cancer antibodies which are useful in treating a cancerous
19 disease. For the purpose of this document, the terms "antibody" and "monoclonal antibody"
20 (mAb) may be used interchangeably and refer to intact immunoglobulins produced by
21 hybridomas (e.g. murine or human), immunoconjugates and, as appropriate, immunoglobulin
22 fragments and recombinant proteins derived from immunoglobulins, such as chimeric and

1 humanized immunoglobulins, F(ab') and F(ab')₂ fragments, single-chain antibodies,
2 recombinant immunoglobulin variable regions (Fv)s, fusion proteins etc. For the purpose of
3 this document, the term "tissue sample" is understood to mean at least one cell or an aggregate
4 of cells obtained from a mammal. It is well recognized in the art that some amino acid
5 sequence can be varied in a polypeptide without significant effect on the structure or function
6 of the protein. In the molecular rearrangement of antibodies, modifications in the nucleic or
7 amino acid sequence of the backbone region can generally be tolerated. These include, but are
8 not limited to, substitutions (preferred are conservative substitutions), deletions or additions.
9 Furthermore, it is within the purview of this invention to conjugate standard chemotherapeutic
10 modalities, e.g. radionuclides, with the CDMAB of the instant invention, thereby focusing the
11 use of said chemotherapeutics. The CDMAB can also be conjugated to toxins, cytotoxic
12 moieties, enzymes e.g. biotin conjugated enzymes, or hematogenous cells, thereby forming
13 antibody conjugates. Such conjugated moieties are illustrated herein as conjugated to the
14 monoclonal antibody derived from the hybridoma cell line designated 6BD-25; similar
15 antibody conjugates could be formed utilizing the monoclonal antibody derived from the
16 hybridoma cell line designated 5LAC-23.

17 This application utilizes the method for producing patient specific anti-cancer
18 antibodies as taught in the '357 patent for isolating hybridoma cell lines which encode for
19 cancerous disease modifying monoclonal antibodies. These antibodies can be made
20 specifically for one tumor and thus make possible the customization of cancer therapy. Within
21 the context of this application, anti-cancer antibodies having either cell-killing (cytotoxic) or
22 cell-growth inhibiting (cytostatic) properties will hereafter be referred to as cytotoxic. These
23 antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat

1 tumor metastases.

2 The prospect of individualized anti-cancer treatment will bring about a change in the
3 way a patient is managed. A likely clinical scenario is that a tumor sample is obtained at the
4 time of presentation, and banked. From this sample, the tumor can be typed from a panel of
5 pre-existing cancerous disease modifying antibodies. The patient will be conventionally
6 staged but the available antibodies can be of use in further staging the patient. The patient can
7 be treated immediately with the existing antibodies and/or a panel of antibodies specific to the
8 tumor can be produced either using the methods outlined herein or through the use of phage
9 display libraries in conjunction with the screening methods herein disclosed. All the
10 antibodies generated will be added to the library of anti-cancer antibodies since there is a
11 possibility that other tumors can bear some of the same epitopes as the one that is being
12 treated. The antibodies produced according to this method may be useful to treat cancerous
13 disease in any number of patients who have cancers that bind to these antibodies.

14 Using substantially the process of US 6,180,370 and as outlined in US 6,657,048, the
15 mouse monoclonal antibodies 6BD-25 and 5LAC-23 were obtained following immunization
16 of mice with cells from a patient's breast and lung tumor biopsy respectively. The 6BD-25
17 antigen was initially not detected on a variety of human normal and cancer cell lines by cell
18 ELISA/FACS. After increasing the sensitivity of the assay through conjugation of the 6BD-25
19 antibodies to biotin, the antigen was detected on the breast cancer cell line MDA-MB-231 and
20 the ovarian cancer cell lines C-13, OVCA-429 and OV2008. The breast cancer cell line
21 Hs574.T was susceptible to the cytotoxic effects of unpurified 6BD-25. The breast cancer cell
22 line MCF-7, the ovarian cancer cell line OVCAR-3 and the colon cancer cell line SW1116

1 were the only 3 cancer cell lines tested that were susceptible to the cytotoxic effects of purified
2 6BD-25. Through the use of FACS analysis, the antigen for 5LAC-23 was detected on the
3 SW620 colon cancer cell line and not on any of the other cell lines tested. The breast
4 (Hs574.T), lung (NCI-H661) and skin (A2058) cancer cell line were susceptible to the
5 cytotoxic effects of unpurified 5LAC-23. The ovarian cancer cell line OVCAR-3 was the only
6 cancer cell line tested that was susceptible to the cytotoxic effects of purified 5LAC-23.

7 The result of 6BD-25 cytotoxicity against OVCAR-3 and SW1116 cells in culture was
8 further extended by its anti-tumor activity towards these cells when transplanted into mice. In
9 an *in vivo* model of colon cancer, the human SW1116 cells were implanted subcutaneously at
10 the scruff of the neck while for an *in vivo* model of ovarian cancer, the human OVCAR-3 cells
11 were implanted intraperitoneally. For both models, immunodeficient mice were used as they
12 are incapable of rejecting the human tumor cells due to a lack of certain immune cells. Pre-
13 clinical xenograft tumor models are considered valid predictors of therapeutic efficacy.
14 Xenografts in mice grow as solid tumors developing stroma, central necrosis and neo-
15 vasculature. The tumor cell lines OVCAR-3 and SW1116 have been evaluated as an *in vivo*
16 xenograft model in immunodeficient mice. The good engraftment or 'take-rate' of the
17 OVCAR-3 and SW1116 tumors and the sensitivity of the tumors to standard chemotherapeutic
18 agents have characterized them as suitable models. The parental cell line and variants of the
19 cell line have been used in xenograft tumor models to evaluate a wide range of therapeutic
20 agents.

21 In the preventative *in vivo* model of human colon cancer, 6BD-25 was given to mice
22 one day prior to implantation of tumor cells followed by weekly injections for a period of 7
23 weeks. 6BD-25 treatment was significantly ($p=0.001$) more effective in suppressing tumor

1 growth during the treatment period than buffer control. At the end of the treatment phase,
2 mice given 6BD-25 had tumors that grew to only 54 percent of the control group. During the
3 post treatment follow-up period, the treatment effects of 6BD-25 were sustained and the mean
4 tumor volume in the treated groups continued to be significantly smaller than controls until the
5 end of the measurement phase ($p=0.002$). 6BD-25 treatment appeared safe, as it did not induce
6 any signs of toxicity, including reduced body weight or other signs of clinical distress. Thus,
7 6BD-25 treatment was efficacious as it delayed tumor growth compared to the control-treated
8 group in a well-established model of human colon cancer.

9 Besides the preventative *in vivo* tumor model of colon cancer, 6BD-25 demonstrated
10 anti-tumor activity against OVCAR-3 cells in a preventative ovarian *in vivo* tumor model. In
11 this xenograft tumor model, OVCAR-3 ovarian cancer cells were transplanted intraperitoneally
12 into immunodeficient mice with treatment commencing the day after implantation for a total of
13 10 doses. Treatment with 6BD-25 was compared to a buffer control. Body weight was used
14 as a surrogate measure of tumor progression. Increased body weight is indicative of tumor
15 burden since the weight gain is caused by ascites formation. At day 80 post-implantation (16
16 days after the end of treatment), the mice in the treatment group had body weights significantly
17 less than the control group ($p=0.002$). There was also a significant survival benefit with
18 treatment of 6BD-25 versus the buffer control ($p<0.02$). Again, 6BD-25 treatment appeared
19 safe, as it did not induce any signs of toxicity or clinical distress. The anti-tumor activity of
20 6BD-25 and its apparent lack of toxicity make it an attractive anti-cancer therapeutic agent.

21 In all, this invention teaches the use of the 6BD-25 and 5LAC-23 antigens as targets for
22 therapeutic agents and that when administered, 6BD-25 can reduce the tumor burden in a
23 mammal with a cancer expressing the antigen, and can also lead to prolonged survival of the

1 treated mammal. The efficacy of 6BD-25 treatment *in vivo* and the concomitant undetectable
2 or low level of antigen expression on the SW1116 and OVCAR-3 cells respectively, illustrates
3 that the level of antigen expression does not necessarily correlate with *in vivo* efficacy.
4 Furthermore, this invention also teaches that detecting the 6BD-25 and 5LAC-23 antigen in
5 cancerous cells can be useful for the diagnosis, prediction of therapy, and prognosis of
6 mammals bearing tumors that express this antigen.

7 If a patient is refractory to the initial course of therapy or metastases develop, the
8 process of generating specific antibodies to the tumor can be repeated for re-treatment.
9 Furthermore, the anti-cancer antibodies can be conjugated to red blood cells obtained from that
10 patient and re-infused for treatment of metastases. There have been few effective treatments
11 for metastatic cancer and metastases usually portend a poor outcome resulting in death.
12 However, metastatic cancers are usually well vascularized and the delivery of anti-cancer
13 antibodies by red blood cells can have the effect of concentrating the antibodies at the site of
14 the tumor. Even prior to metastases, most cancer cells are dependent on the host's blood
15 supply for their survival and anti-cancer antibodies conjugated to red blood cells can be
16 effective against *in situ* tumors as well. Alternatively, the antibodies may be conjugated to
17 other hematogenous cells, e.g. lymphocytes, macrophages, monocytes, natural killer cells, etc.

18 There are five classes of antibodies and each is associated with a function that is
19 conferred by its heavy chain. It is generally thought that cancer cell killing by naked
20 antibodies are mediated either through antibody-dependent cell-mediated cytotoxicity (ADCC)
21 or complement-dependent cytotoxicity (CDC). For example murine IgM and IgG2a antibodies
22 can activate human complement by binding the C-1 component of the complement system

1 thereby activating the classical pathway of complement activation which can lead to tumor
2 lysis. For human antibodies, the most effective complement-activating antibodies are
3 generally IgM and IgG1. Murine antibodies of the IgG2a and IgG3 isotype are effective at
4 recruiting cytotoxic cells that have Fc receptors which will lead to cell killing by monocytes,
5 macrophages, granulocytes and certain lymphocytes. Human antibodies of both the IgG1 and
6 IgG3 isotype mediate ADCC.

7 Another possible mechanism of antibody-mediated cancer killing may be through the
8 use of antibodies that function to catalyze the hydrolysis of various chemical bonds in the cell
9 membrane and its associated glycoproteins or glycolipids, so-called catalytic antibodies.

10 There are two additional mechanisms of antibody-mediated cancer cell killing which
11 are more widely accepted. The first is the use of antibodies as a vaccine to induce the body to
12 produce an immune response against the putative antigen that resides on the cancer cell. The
13 second is the use of antibodies to target growth receptors and interfere with their function or to
14 down regulate that receptor so that its function is effectively lost.

15 The clinical utility of a cancer drug is based on the benefit of the drug under an
16 acceptable risk profile to the patient. In cancer therapy survival has generally been the most
17 sought after benefit, however there are a number of other well-recognized benefits in addition
18 to prolonging life. These other benefits, where treatment does not adversely affect survival,
19 include symptom palliation, protection against adverse events, prolongation in time to
20 recurrence or disease-free survival, and prolongation in time to progression. These criteria are
21 generally accepted and regulatory bodies such as the U.S. Food and Drug Administration
22 (F.D.A.) approve drugs that produce these benefits (Hirschfeld et al. Critical Reviews in

1 Oncology/Hematology 42:137-143 2002). In addition to these criteria it is well recognized that
2 there are other endpoints that may presage these types of benefits. In part, the accelerated
3 approval process granted by the U.S. F.D.A. acknowledges that there are surrogates that will
4 likely predict patient benefit. As of year-end (2003), there have been sixteen drugs approved
5 under this process, and of these, four have gone on to full approval, i.e., follow-up studies have
6 demonstrated direct patient benefit as predicted by surrogate endpoints. One important
7 endpoint for determining drug effects in solid tumors is the assessment of tumor burden by
8 measuring response to treatment (Therasse et al. Journal of the National Cancer Institute
9 92(3):205-216 2000). The clinical criteria (RECIST criteria) for such evaluation have been
10 promulgated by Response Evaluation Criteria in Solid Tumors Working Group, a group of
11 international experts in cancer. Drugs with a demonstrated effect on tumor burden, as shown
12 by objective responses according to RECIST criteria, in comparison to the appropriate control
13 group tend to, ultimately, produce direct patient benefit. In the pre-clinical setting tumor
14 burden is generally more straightforward to assess and document. In that pre-clinical studies
15 can be translated to the clinical setting, drugs that produce prolonged survival in pre-clinical
16 models have the greatest anticipated clinical utility. Analogous to producing positive
17 responses to clinical treatment, drugs that reduce tumor burden in the pre-clinical setting may
18 also have significant direct impact on the disease. Although prolongation of survival is the
19 most sought after clinical outcome from cancer drug treatment, there are other benefits that
20 have clinical utility and it is clear that tumor burden reduction, which may correlate to a delay
21 in disease progression, extended survival or both, can also lead to direct benefits and have
22 clinical impact (Eckhardt et al. Developmental Therapeutics: Successes and Failures of
23 Clinical Trial Designs of Targeted Compounds; ASCO Educational Book, 39th Annual

1 Meeting, 2003, pages 209-219).

2 Accordingly, it is an objective of the invention to utilize a method for producing
3 cancerous disease modifying antibodies from cells derived from a particular individual which
4 are cytotoxic with respect to cancer cells while simultaneously being relatively non-toxic to
5 non-cancerous cells, in order to isolate hybridoma cell lines and the corresponding isolated
6 monoclonal antibodies and antigen binding fragments thereof for which said hybridoma cell
7 lines are encoded.

8 It is an additional objective of the invention to teach CDMAB and antigen binding
9 fragments thereof.

10 It is a further objective of the instant invention to produce CDMAB whose cytotoxicity
11 is mediated through ADCC.

12 It is yet an additional objective of the instant invention to produce CDMAB whose
13 cytotoxicity is mediated through CDC.

14 It is still a further objective of the instant invention to produce CDMAB whose
15 cytotoxicity is a function of their ability to catalyze hydrolysis of cellular chemical bonds.

16 A still further objective of the instant invention is to produce CDMAB which are useful
17 in a binding assay for diagnosis, prognosis, and monitoring of cancer.

18 Other objects and advantages of this invention will become apparent from the
19 following description wherein, by way of illustration and example, certain embodiments of this
20 invention are set forth.

21 Brief Description of the Figures:

1 Figure 1. Representative FACS histograms of 6BD-25, 5LAC-23 and anti-Fas (positive
2 control) antibodies directed against several cancer and non-cancer cell lines.

3 Figure 2. Effect of 6BD-25 on tumor growth in a preventative SW1116 colon cancer model.
4 The dashed line indicates the period during which the antibody was administered. Data points
5 represent the mean +/- SEM.

6 Figure 3. Effect of 6BD-25 on body weight in a preventative OVCAR-3 ovarian cancer
7 model. The dashed line indicates the period during which the antibody was administered. Data
8 points represent the mean +/- SEM.

9 Figure 4. Survival of tumor-bearing mice after treatment with 6BD-25 or buffer control. Mice
10 were monitored for survival for over 240 days post-treatment.

11

12 Detailed Description Of The Invention:

13 Example 1

14 Hybridoma Production – Hybridoma Cell Lines: 6BD-25 and 5LAC-23

15 The hybridoma cell lines 6BD-25 and 5LAC-23 were deposited, in accordance with the
16 Budapest Treaty, with the American Type Culture Collection (ATCC), 10801 University
17 Blvd., Manassas, VA 20110-2209 on December 9, 2003, under Accession Number PTA-5691
18 and PTA-5690 respectively. In accordance with 37 CFR 1.808, the depositors assure that all
19 restrictions imposed on the availability to the public of the deposited materials will be
20 irrevocably removed upon the granting of a patent. The derivation of the clone, the
21 supernatant and cell ELISA screening of 6BD-25 and 5LAC-23 has previously been described
22 in US 6,657,048.

1 6BD-25 and 5LAC-23 monoclonal antibodies were produced by culturing the
2 hybridomas in CL-1000 flasks (BD Biosciences, Oakville, ON) with collections and reseeding
3 occurring twice/week. The antibodies were purified according to standard antibody
4 purification procedures with Protein G Sepharose 4 Fast Flow (Amersham Biosciences, Baie
5 d'Urfé, QC).

6 6BD-25 and 5LAC-23 were compared to a number of both positive (anti-Fas (EOS9.1,
7 IgM, kappa, 20 micrograms/mL, eBioscience, San Diego, CA), anti-EGFR (C225, IgG1,
8 kappa, 5 microgram/mL, Cedarlane, Hornby, ON), Cycloheximide (100 micromolar, Sigma,
9 Oakville, ON), NaN₃ (0.1%, Sigma, Oakville, ON)) and negative (107.3 (anti-TNP, IgG1,
10 kappa, 20 microgram/mL, BD Biosciences, Oakville, ON), G155-178 (anti-TNP, IgG2a,
11 kappa, 20 microgram/mL, BD Biosciences, Oakville, ON), MPC-11 (antigenic specificity
12 unknown, IgG2b, kappa, 20 microgram/mL), J606 (anti-fructosan, IgG3, kappa, 20
13 microgram/mL), IgG Buffer (2%), IgM buffer (2%)) controls in a cytotoxicity assay (Table 1).
14 Breast cancer (MDA-MB-231 (MB-231), MDA-MB-468 (MB-468), MCF-7), colon cancer
15 (HT-29, SW1116, SW620), lung cancer (NCI-H460), ovarian cancer (OVCAR-3), prostate
16 cancer (PC-3), and non-cancer (CCD-27sk, Hs888.Lu) cell lines were tested (all from the
17 ATCC, Manassas, VA). The Live/Dead cytotoxicity assay was obtained from Molecular
18 Probes (Eugene,OR). The assays were performed according to the manufacturer's instructions
19 with the changes outlined below. Cells were plated before the assay at the predetermined
20 appropriate density. After 2 days, purified antibody or controls were diluted into media, and
21 then 100 microliters were transferred to the cell plates and incubated in a 5 percent CO₂
22 incubator for 5 days. The plate was then emptied by inverting and blotted dry. Room
23 temperature DPBS containing MgCl₂ and CaCl₂ was dispensed into each well from a multi-

1 channel squeeze bottle, tapped three times, emptied by inversion and then blotted dry. 50
2 microliters of the fluorescent calcein dye diluted in DPBS containing $MgCl_2$ and $CaCl_2$ was
3 added to each well and incubated at $37^{\circ}C$ in a 5 percent CO_2 incubator for 30 minutes. The
4 plates were read in a Perkin-Elmer HTS7000 fluorescence plate reader and the data was
5 analyzed in Microsoft Excel and the results were tabulated in Table 1. The data represented an
6 average of four experiments tested in triplicate and presented qualitatively in the following
7 fashion: 4/4 experiments greater than threshold cytotoxicity (+++), 3/4 experiments greater
8 than threshold cytotoxicity (++), 2/4 experiments greater than threshold cytotoxicity (+).
9 Unmarked cells in Table 1 represent inconsistent or effects less than the threshold cytotoxicity.
10 The chemical cytotoxic agents induced their expected cytotoxicity while a number of other
11 antibodies which were included for comparison also performed as expected given the
12 limitations of biological cell assays. The 6BD-25 antibody demonstrated cytotoxicity in breast,
13 ovarian and colon cancer cell lines selectively, while having no effect on non-transformed
14 normal cells. The 5LAC-23 antibody demonstrated cytotoxicity in the ovarian cancer cell line
15 selectively while also having no effect on non-transformed normal cells. The antibodies 6BD-
16 25 and 5LAC-23 were selective in their activity since not all cancer cell types were
17 susceptible. Furthermore, 6BD-25 and 5LAC-23 demonstrated functional specificity since they
18 did not produce cytotoxicity against non-cancer cell types, which is an important therapeutic
19 factor.

1 Table 1: *In Vitro* Cytotoxicity of 6BD-25 and 5LAC-23

		Cell Line										
		Antibody	MB-231	MB-468	MCF-7	HT-29	SW1116	SW620	NCI H460	OVCAR	PC-3	CCD 27sk
Negative Controls	6BD-25			+		++			+			
	5LAC-23								++			
	IgM buffer	+										
	IgG1 isotype											
Positive Controls	CHX	++	+++	+++	+++	+++	++	++	+++	+++	+++	+++
	NaN ₃	+++	+++	+++	+++	++		+++	+++	+++		
	anti-EGFR		+++			+++					++	
	anti-Fas			++					+++	+		

2

3 Binding of 6BD-25 to the above-mentioned panel of cancer and normal cell lines was
4 assessed by flow cytometry (FACS). Cells were prepared for FACS by initially washing the
5 cell monolayer with DPBS (without Ca⁺⁺ and Mg⁺⁺). Cell dissociation buffer (INVITROGEN,
6 Burlington, ON) was then used to dislodge the cells from their cell culture plates at 37°C.
7 After centrifugation and collection, the cells were resuspended in Dulbecco's phosphate
8 buffered saline containing MgCl₂, CaCl₂ and 25 percent fetal bovine serum at 4°C (wash
9 media) and counted, aliquoted to appropriate cell density, spun down to pellet the cells and
10 resuspended in staining media (DPBS containing MgCl₂ and CaCl₂) containing 6BD-25
11 (unconjugated or conjugated with biotin), 5LAC-23 or control antibodies (isotype control or
12 anti-Fas) at 20 micrograms/mL on ice for 30 minutes. Conjugating 6BD-25 to biotin was
13 performed with biotinylation reagent (Pierce E2-Link Sulfo-NHS-LC-biotin, Rockford, IL).
14 The biotinylation reagent was added in 20 times molar excess to 6BD-25 and incubated for 2
15 hrs at room temperature with shaking. The biotinylated 6BD-25 was then dialyzed overnight
16 against PBS at 4°C. Prior to the addition of Alexa Fluor 488-conjugated secondary antibody
17 (for unconjugated primary antibodies) or streptavidin R-phycoerythrin conjugated secondary
18 antibody (for biotinylated 6BD-25), the cells were washed once with wash media. The

1 appropriate secondary antibody in staining media was then added for 20 minutes. The cells
2 were then washed for the final time and resuspended in staining media containing 1
3 microgram/mL propidium iodide. Flow cytometric acquisition of the cells was assessed by
4 running samples on a FACScan using the CellQuest software (BD Biosciences, Oakville, ON).
5 The forward (FSC) and side scatter (SSC) of the cells were set by adjusting the voltage and
6 amplitude gains on the FSC and SSC detectors. The detectors for the three fluorescence
7 channels (FL1, FL2, and FL3) were adjusted by running cells stained with purified isotype
8 control antibody followed by the appropriate secondary antibody such that cells had a uniform
9 peak with a median fluorescent intensity of approximately 1-5 units. Live cells were acquired
10 by gating for FSC and propidium iodide exclusion. For each sample, approximately 10,000
11 live cells were acquired for analysis and the results presented in Table 2. Table 2 tabulated the
12 mean fluorescence intensity fold increase above isotype control and is presented qualitatively
13 as: less than 1.5 (-); 1.5 to 2 (+); 2 to 3 (++); 3 to 10 (+++) and >10 (++++).

14 Representative histograms of 6BD-25 and 5LAC-23 antibodies were compiled for
15 Figure 1. Unconjugated 6BD-25 did not initially bind any cell lines tested by FACS.
16 However, after increasing the sensitivity of the assay by conjugating 6BD-25 to biotin, it was
17 demonstrated that a low level of antigen is present on the surface of MDA-MB-231, C-13,
18 OVCA-429 and OV2008 cancer cells. By FACS, 5LAC-23 showed high and specific binding
19 to the colon cancer cell line SW620. For both 6BD-25 and 5LAC-23, this was further evidence
20 that the degree of binding was not necessarily predictive of the outcome of antibody ligation of
21 its cognate antigen, and was a non-obvious finding. This suggested that the context of antibody
22 ligation in different cells was determinative of cytotoxicity rather than just antibody binding.

23

1 Table 2: FACS Analysis of 6BD-25 and 5LAC-23

Antibody	Isotype	Cell Line													
		CCD-27sk	PC-3	NCI-H460	Hs888.Lu	HT-29	SW620	SW1116	MB-231	MB-468	MCF-7	OV2008	C13	OVCA-429	OVCAR-3
6BD-25	IgM, k	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Biotinylated 6BD-25	IgM, k							-	+			+++	+	+	+
5LAC-23	IgM, k	-	-	-	-	-	+++	-	-	-	-				-
anti-Fas (+ control)	IgM, k	++++	+	+++	++++	+++	-	+++	++	+	+++	+++	+++	++	+++

2

3 Example 2

4 *In Vivo* Colon Preventative Tumor Experiments

5 With reference to the data shown in Figure 2, 4 to 8 week old, female SCID mice were
6 implanted with 5 million SW1116 human colon cancer cells in 100 microliters saline injected
7 subcutaneously in the scruff of the neck. The mice were randomly divided into 2 treatment
8 groups of 10. On the day prior to implantation 20 mg/kg of 6BD-25 test antibody or buffer
9 control was administered intraperitoneally at a volume of 300 microliters after dilution from
10 the stock concentration with a diluent that contained 500 mM NaCl, 20 mM Na₂HPO₄•7H₂O
11 and 20 mM NaH₂PO₄•H₂O. The antibodies were then administered once per week for a period
12 of 7 weeks in the same fashion.

13 Tumor growth was measured roughly every 7th day with calipers for up to 16 weeks or
14 until individual animals reached the Canadian Council for Animal Care (CCAC) end-points or
15 day 112. Body weights of the animals were recorded for the duration of the study. At the end
16 of the study all animals were euthanised according to CCAC guidelines.

17 There were no clinical signs of toxicity throughout the study. Data was analyzed using
18 the independent samples test and significance was determined using the t-test for equality of
19 means. At day 50 (1 day after final treatment), the tumor volume in the 6BD-25 treated group
20 was 54 percent of the buffer control (p=0.001). Delayed growth of the tumor continued past
21 the treatment period. At day 112 (63 days post-treatment), tumor volume in the antibody

1 treatment group was 59 percent of the buffer control ($p=0.002$). In summary, 6BD-25 antibody
2 treatment reduced tumor burden in comparison to buffer control in a well-recognized model of
3 human colon cancer. These results suggest a potential pharmacologic and pharmaceutical
4 benefit of this antibody (6BD-25) as a therapy in other mammals, including man.

5 6 Example 3

7 *In Vivo* Ovarian Preventative Tumor Experiments:

8 With reference to the data shown in Figures 3 and 4, 4 to 8 week old, female SCID
9 mice were implanted with 5 million OVCAR-3 human ovarian cancer cells in 1000 microliters
10 saline injected intraperitoneally. The mice were randomly divided into 2 treatment groups of
11 10. On the day after implantation 20 mg/kg of 6BD-25 test antibody or antibody buffer was
12 administered intraperitoneally at a volume of 300 microliters after dilution from the stock
13 concentration with a diluent that contained 500 mM NaCl, 20 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ and 20 mM
14 $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$. The antibodies were then administered once per week for a period of 9 weeks
15 in the same fashion.

16 Body weight was measured roughly every 7th day for up to 11 weeks or until
17 individual animals reached the Canadian Council for Animal Care (CCAC) end-points or day
18 76. Body weights of the animals were recorded for the duration of the study. At the end of the
19 study all animals were euthanised according to CCAC guidelines.

20 There were no clinical signs of toxicity throughout the study. Body weight was used as
21 a surrogate measure of tumor progression (Figure 3). Increased body weight is indicative of
22 tumor burden since the weight gain is caused by ascites formation. Significance was
23 determined using the Dunnett's t-test. At day 80 post-implantation (16 days after the end of

1 treatment), mice in the 6BD-25 treatment group had body weights significantly less than the
2 buffer control group ($p=0.002$). There was also enhanced survival with treatment with 6BD-
3 25 compared to the buffer control (Figure 4) as determined by the log-rank test. Mice in the
4 control group had a median survival of 87.0 days versus 107.5 days in the 6BD-25 treatment
5 group ($p<0.02$). Also, all mice in the buffer treatment group had died by day 120 post-
6 implantation (56 days after treatment). In the antibody treatment group, there was still 1
7 mouse alive at day 250 post-treatment (186 days post-treatment). In summary, 6BD-25
8 antibody treatment prevented tumor burden in comparison to buffer control in another well-
9 recognized model of human cancer disease. 6BD-25 also enhanced survival in an ovarian
10 xenograft model.

11 In toto, 6BD-25 is significantly more effective than buffer control in suppressing tumor
12 growth in a preventative tumor xenograft model of colon and ovarian cancer in SCID mice.
13 Treatment with 6BD-25 also showed a survival benefit in a well-recognized model of human
14 ovarian cancer disease suggesting pharmacologic and pharmaceutical benefits of this antibody
15 for therapy in other mammals, including man. Furthermore, the undetectable or low level of
16 antigen expression on the SW1116 and OVCAR-3 cells respectively, illustrates that the level
17 of antigen expression does not necessarily correlate with *in vivo* efficacy.

18 All patents and publications mentioned in this specification are indicative of the levels
19 of those skilled in the art to which the invention pertains. All patents and publications are
20 herein incorporated by reference to the same extent as if each individual publication was
21 specifically and individually indicated to be incorporated by reference.

22 It is to be understood that while a certain form of the invention is illustrated, it is not to
23 be limited to the specific form or arrangement of parts herein described and shown. It will be

1 apparent to those skilled in the art that various changes may be made without departing from
2 the scope of the invention and the invention is not to be considered limited to what is shown
3 and described in the specification. One skilled in the art will readily appreciate that the
4 present invention is well adapted to carry out the objects and obtain the ends and advantages
5 mentioned, as well as those inherent therein. Any oligonucleotides, peptides, polypeptides,
6 biologically related compounds, methods, procedures and techniques described herein are
7 presently representative of the preferred embodiments, are intended to be exemplary and are
8 not intended as limitations on the scope. Changes therein and other uses will occur to those
9 skilled in the art which are encompassed within the spirit of the invention and are defined by
10 the scope of the appended claims. Although the invention has been described in connection
11 with specific preferred embodiments, it should be understood that the invention as claimed
12 should not be unduly limited to such specific embodiments. Indeed, various modifications of
13 the described modes for carrying out the invention which are obvious to those skilled in the art
14 are intended to be within the scope of the following claims.

15

16

17

18

19

20

21

22

23